VolitionRx's veterinary subsidiary wins 12.5% equity stake from Texas A&M

Texas A&M also will provide its expertise and conduct specified research and development activities 

VolitionRx - VolitionRx Limited of Belgium announces Texas A&M University takes roughly a 12.5% equity stake in its subsidiary Volition Veterinary Diagnostics Development LLC
The College of Veterinary Medicine & Biomedical Sciences will work with Volition's subsidiary

VolitionRx Limited (NYSEAMERICAN:VNRX) announced Friday that Texas A&M University has taken roughly a 12.5% equity stake in its subsidiary Volition Veterinary Diagnostics Development LLC.

In a statement, Belgium-based company said that Texas A&M also will provide its expertise and conduct specified research and development activities. 

Under the agreement, Volition (through its subsidiaries) said it will provide certain parts of its intellectual property associated with its proprietary Nu.Q platform and assays as well as an aggregate of $400,000 to the school and affiliated entities towards the collaboration. 

READ: VolitionRx hits milestone in Nu.Q Capture blood-based cancer-detection technology

Volition’s NuQ platform looks for molecular signatures of cancer by focusing on the nucleosomes – a section of DNA wrapped around a core of proteins – in the blood. As cancer cells multiply, they are modified in a way that distinguishes them from healthy cells and the traits of the malignant disease appear on the nucleosomes, which are analyzed by the platform.

The company and the university together have been studying a version of its blood-based tests for animals called Nu.Q Vet after discovering that nucleosomes in the blood can also be detected in dogs.

"The Texas A&M College of Veterinary Medicine & Biomedical Sciences is excited to be working with Volition to develop tests for the early detection of cancer and other diseases in animals," said Dr Eleanor Green, the Carl B King Dean of Veterinary Medicine at Texas A&M.

"The research and clinical trials conducted by CVM's veterinary oncologists work on the cutting-edge of medicine and have benefitted both humans and animals. The goal of this project with Volition is to provide all veterinarians with simple, affordable, routine blood tests that can help identify disease early and improve the lives of both animals and the people who love them."

CEO Cameron Reynolds noted he "enjoyed the hospitality of Texas A&M and (is) very impressed with the caliber of personnel and fantastic facilities in the veterinary school." 

The company’s stock recently traded up 3.7% to $5.89 a share in New York. 

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Quick facts: VolitionRx

Price: 3.04 USD

Market Cap: $145.68 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...


VolitionRX progressing towards launch of first commercial products using...

VolitionRx Limited's (NYSEAMERICAN:VNRX) Cameron Reynolds tells Proactive the firm rounded out the second quarter with $21.3 million in cash and equivalents compared to $12 million in the same quarter a year ago. The company's now tested two independent cohorts of COVID-19 positive patients with...

on 08/14/2020

2 min read